116 related articles for article (PubMed ID: 36669477)
1. SMARCA4 vulnerability in H3K27M midline glioma: A silver bullet for a lethal disease.
Chen CCL; Andrade AF; Jabado N
Mol Cell; 2023 Jan; 83(2):163-164. PubMed ID: 36669477
[TBL] [Abstract][Full Text] [Related]
2. BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma.
Panditharatna E; Marques JG; Wang T; Trissal MC; Liu I; Jiang L; Beck A; Groves A; Dharia NV; Li D; Hoffman SE; Kugener G; Shaw ML; Mire HM; Hack OA; Dempster JM; Lareau C; Dai L; Sigua LH; Quezada MA; Stanton AJ; Wyatt M; Kalani Z; Goodale A; Vazquez F; Piccioni F; Doench JG; Root DE; Anastas JN; Jones KL; Conway AS; Stopka S; Regan MS; Liang Y; Seo HS; Song K; Bashyal P; Jerome WP; Mathewson ND; Dhe-Paganon S; Suvà ML; Carcaboso AM; Lavarino C; Mora J; Nguyen QD; Ligon KL; Shi Y; Agnihotri S; Agar NYR; Stegmaier K; Stiles CD; Monje M; Golub TR; Qi J; Filbin MG
Cancer Discov; 2022 Dec; 12(12):2880-2905. PubMed ID: 36305736
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Rewiring Underlies SMARCA4-Dependent Maintenance of Progenitor State in Pediatric H3K27M Diffuse Midline Glioma.
Beytagh MC; Weiss WA
Cancer Discov; 2022 Dec; 12(12):2730-2732. PubMed ID: 36458436
[TBL] [Abstract][Full Text] [Related]
4. Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas.
Mota M; Sweha SR; Pun M; Natarajan SK; Ding Y; Chung C; Hawes D; Yang F; Judkins AR; Samajdar S; Cao X; Xiao L; Parolia A; Chinnaiyan AM; Venneti S
Proc Natl Acad Sci U S A; 2023 May; 120(18):e2221175120. PubMed ID: 37094128
[TBL] [Abstract][Full Text] [Related]
5. Epigenome Programming by H3.3K27M Mutation Creates a Dependence of Pediatric Glioma on SMARCA4.
Mo Y; Duan S; Zhang X; Hua X; Zhou H; Wei HJ; Watanabe J; McQuillan N; Su Z; Gu W; Wu CC; Vakoc CR; Hashizume R; Chang K; Zhang Z
Cancer Discov; 2022 Dec; 12(12):2906-2929. PubMed ID: 36305747
[TBL] [Abstract][Full Text] [Related]
6. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
Alessi JV; Ricciuti B; Spurr LF; Gupta H; Li YY; Glass C; Nishino M; Cherniack AD; Lindsay J; Sharma B; Felt KD; Rodig SJ; Cheng ML; Sholl LM; Awad MM
J Thorac Oncol; 2021 Jul; 16(7):1176-1187. PubMed ID: 33845210
[TBL] [Abstract][Full Text] [Related]
7. SWI/SNF gene variants and glioma risk and outcome.
Amankwah EK; Thompson RC; Nabors LB; Olson JJ; Browning JE; Madden MH; Egan KM
Cancer Epidemiol; 2013 Apr; 37(2):162-5. PubMed ID: 23276717
[TBL] [Abstract][Full Text] [Related]
8. Switch/sucrose-non-fermentable (SWI/SNF) complex (SMARCA4, SMARCA2, INI1/SMARCB1)-deficient colorectal carcinomas are strongly associated with microsatellite instability: an incidence study in 4508 colorectal carcinomas.
Ahadi MS; Fuchs TL; Clarkson A; Sheen A; Sioson L; Chou A; Gill AJ
Histopathology; 2022 May; 80(6):906-921. PubMed ID: 34951482
[TBL] [Abstract][Full Text] [Related]
9. SWI/SNF complex-deficient soft tissue neoplasms: An update.
Schaefer IM; Hornick JL
Semin Diagn Pathol; 2021 May; 38(3):222-231. PubMed ID: 32646614
[TBL] [Abstract][Full Text] [Related]
10. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.
Wilson BG; Helming KC; Wang X; Kim Y; Vazquez F; Jagani Z; Hahn WC; Roberts CW
Mol Cell Biol; 2014 Mar; 34(6):1136-44. PubMed ID: 24421395
[TBL] [Abstract][Full Text] [Related]
11. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
[TBL] [Abstract][Full Text] [Related]
12. Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.
Naito T; Udagawa H; Umemura S; Sakai T; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuboi M; Ishii G; Goto K
Lung Cancer; 2019 Dec; 138():35-42. PubMed ID: 31630044
[TBL] [Abstract][Full Text] [Related]
13. Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia.
Rago F; Rodrigues LU; Bonney M; Sprouffske K; Kurth E; Elliott G; Ambrose J; Aspesi P; Oborski J; Chen JT; McDonald ER; Mapa FA; Ruddy DA; Kauffmann A; Abrams T; Bhang HC; Jagani Z
Mol Cancer Res; 2022 Mar; 20(3):361-372. PubMed ID: 34799403
[TBL] [Abstract][Full Text] [Related]
14. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
15. The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia.
Pottier N; Yang W; Assem M; Panetta JC; Pei D; Paugh SW; Cheng C; Den Boer ML; Relling MV; Pieters R; Evans WE; Cheok MH
J Natl Cancer Inst; 2008 Dec; 100(24):1792-803. PubMed ID: 19066270
[TBL] [Abstract][Full Text] [Related]
16.
Concepcion CP; Ma S; LaFave LM; Bhutkar A; Liu M; DeAngelo LP; Kim JY; Del Priore I; Schoenfeld AJ; Miller M; Kartha VK; Westcott PMK; Sánchez-Rivera FJ; Meli K; Gupta M; Bronson RT; Riely GJ; Rekhtman N; Rudin CM; Kim CF; Regev A; Buenrostro JD; Jacks T
Cancer Discov; 2022 Feb; 12(2):562-585. PubMed ID: 34561242
[No Abstract] [Full Text] [Related]
17. The SWI/SNF chromatin-remodeling complex status in renal cell carcinomas with sarcomatoid or rhabdoid features.
Kinoshita F; Kohashi K; Sugimoto M; Takamatsu D; Kiyozawa D; Eto M; Oda Y
Virchows Arch; 2020 Nov; 477(5):651-660. PubMed ID: 32447490
[TBL] [Abstract][Full Text] [Related]
18. The ATPase BRG1/SMARCA4 is a protein interaction platform that recruits BAF subunits and the transcriptional repressor REST/NRSF in neural progenitor cells.
Jayaprakash S; Drakulic S; Zhao Z; Sander B; Golas MM
Mol Cell Biochem; 2019 Nov; 461(1-2):171-182. PubMed ID: 31428904
[TBL] [Abstract][Full Text] [Related]
19. Expression inactivation of SMARCA4 by microRNAs in lung tumors.
Coira IF; Rufino-Palomares EE; Romero OA; Peinado P; Metheetrairut C; Boyero-Corral L; Carretero J; Farez-Vidal E; Cuadros M; Reyes-Zurita FJ; Lupiáñez JA; Sánchez-Cespedes M; Slack FJ; Medina PP
Hum Mol Genet; 2015 Mar; 24(5):1400-9. PubMed ID: 25355421
[TBL] [Abstract][Full Text] [Related]
20. SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer.
Xue Y; Meehan B; Fu Z; Wang XQD; Fiset PO; Rieker R; Levins C; Kong T; Zhu X; Morin G; Skerritt L; Herpel E; Venneti S; Martinez D; Judkins AR; Jung S; Camilleri-Broet S; Gonzalez AV; Guiot MC; Lockwood WW; Spicer JD; Agaimy A; Pastor WA; Dostie J; Rak J; Foulkes WD; Huang S
Nat Commun; 2019 Feb; 10(1):557. PubMed ID: 30718506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]